Cyclosporin A-associated changes in red blood cell membrane composition, deformability, blood and plasma viscosity in rats

Acta Haematologica

Volumn 112, Issue 4, 2004, Pages 184-188

  Ademoglu, Evin ^a   Tamer, Sule ^a   Albeniz, Isil ^a   Gokkusu, Cahide ^a   Tanrikulu, Sevda ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Blood viscosity; Cyclosporin A; Membrane lipids; Plasma viscosity; Red blood cell deformability

Indexed keywords

CHOLESTEROL; CYCLOSPORIN A; LIPID; MEMBRANE PROTEIN; PHOSPHOLIPID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD RHEOLOGY; BLOOD VISCOSITY; CELL COMPOSITION; CONTROLLED STUDY; ERYTHROCYTE DEFORMABILITY; ERYTHROCYTE SHAPE; FEMALE; MICROCIRCULATION; NONHUMAN; PLASMA VISCOSITY; PRIORITY JOURNAL; RAT; RAT STRAIN; STATISTICAL SIGNIFICANCE; TOXICITY TESTING;

ANIMALS; BLOOD VISCOSITY; CHOLESTEROL; CYCLOSPORINE; ERYTHROCYTE DEFORMABILITY; ERYTHROCYTE MEMBRANE; FEMALE; MEMBRANE PROTEINS; MICROCIRCULATION; PHOSPHOLIPIDS; RATS; RATS, WISTAR;

EID: 9144252825     PISSN: 00015792     EISSN: None     Source Type: Journal    
DOI: 10.1159/000081269     Document Type: Article

References (50)

1. Mattila PS, Ullman KS, Fiering S, Emmel EA, McCutcheon M, Crabtree GR, Herzenberg LA: The actions of cyclosporin A and FK506 suggest a novel step in the activation of T lymphocytes. EMBO J 1990;9:4425-4433.
2. Borel JF, Baumann G, Chapman I, Donatsch P, Fahr A, Mueller EA, Vigouret JM: In vivo pharmacological effects of cyclosporin and some analogues. Adv Pharmacol 1996;35:115-246.
3. Schreiber SL, Crabtree GR: The mechanism of action of cyclosporin A and FK506. Immunol Today 1992;13/4:136-142.
4. Schwartz RH: A cell culture model for T lymphocyte clonal anergy. Science 1990;248:1349-1356.
5. Remuzzi G, Perico N: Cyclosporine-induced renal dysfunction in experimental animals and humans. Kidney Int Suppl 1995;52:S70-74.
6. Vaziri ND, Liang K, Azad H: Effect of cyclosporine on HMG-CoA reductase, cholesterol 7alpha-hydroxylase, LDL receptor, HDL receptor, VLDL receptor, and lipoprotein lipase expressions. J Pharmacol Exp Ther 2000;294:778-783.
7. Myers BD: Cyclosporine nephrotoxicity. Kidney Int 1986;30:964-974.
8. Penn I: Cancers following cyclosporine therapy. Transplantation 1987;43/1:32-35.
9. Chien S: Rheology in the microcirculation in normal and low flow states. Adv Shock Res 1982;8:71-80.
10. Schwartz RS, Madsen JW, Rybicki AC, Nagel RL: Oxidation of spectrin and deformability defects in diabetic erythrocytes. Diabetes 1991;40:701-708.
11. Ernst E, Krauth U, Resch KL, Paulsen HF: Does blood rheology revert to normal after myocardial infarction? Br Heart J 1990;64:248-250.
12. Piagnerelli M, Boudjeltia KZ, Vanhaeverbeek M, Vincent JL: Red blood cell rheology in sepsis. Intensive Care Med 2003;29:1052-1061.
13. Walzl M, Schied G, Walzl B: Effects of ameliorated haemorheology on clinical symptoms in cerebrovascular disease. Atherosclerosis 1998;139:385-389.
14. Korbut RA, Adamek-Guzik T, Madej J, Korbut R: Endothelial secretagogues and deformability of erythrocytes. J Physiol Pharmacol 2002;53:655-665.
15. MacRury SM, Lennie SE, McColl P, Balendra R, MacCuish AC, Lowe GD: Increased red cell aggregation in diabetes mellitus: Association with cardiovascular risk factors. Diabet Med 1993;10/1:21-26.
16. Schauf B, Aydeniz B, Bayer R, Wallwiener D: The laser diffractoscope - A new and fast system to analyze red blood cell flexibility with high accuracy. Lasers Med Sci 2003;18/1:45-50.
17. Thakkar RR, Wang OL, Zerouga M, Stillwell W, Haq A, Kissling R, Pierce WM, Smith NB, Miller FN, Ehringer WD: Docosahexaenoic acid reverses cyclosporin A-induced changes in membrane structure and function. Biochim Biophys Acta 2000;1474/2:183-195.
18. Vareesangthip K, Nimmannit S, Chuawattana D, Mingkam S, Hanlakorn P, Ong-Aj-Yooth L: Impairment of erythrocyte membrane fluidity in cyclosporine-treated renal transplant patients. Transplant Proc 2001;33:1198-1200.
19. Schut NH, Bilo HJ, Popp-Snijders C, Goedhart PT, Wilmink JM: Erythrocyte deformability, endothelin levels, and renal function in cyclosporin-treated renal transplant recipients: Effects of intervention with fish oil and corn oil. Scand J Clin Lab Invest 1993;53:499-506.
20. McGrath LT, Treacy R, McClean E, Brown JH: Oxidative stress in cyclosporin and azathioprine treated renal transplant patients. Clin Chim Acta 1997;264/1:1-12.
21. Reinhart WH, Usami S, Schmalzer EA, Lee MML, Chien S: Evaluation of red blood cell filterability test: Influences of pore size, haematocrit level and flow rate. J Lab Clin Med 1984;104:501-516.
22. Dodge JT, Mitchell C, Hanahan DJ: The preparation and chemical characteristics of the hemoglobin free ghosts of human erythrocytes. Biochemistry 1962;100:119-224.
23. Laemmli UK: Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970;227:680-685.
24. Folch J, Lees M, Sloane A, Stanley GH: A simple method for the isolation and purification of total lipids from animal tissues. J Biochem 1957;226:497-509.
25. Gomori G: Modification of calorimetric phosphorus determination for use with photoelectric colorimeter. J Lab Clin 1942;27:955-960.
26. Mohandas N: The red blood cell membrane; in Hoffman R, Benz EJ, Shattil SJ, Furie B, Cohen HJ, Silberstein LE (eds): Hematology: Basic, Principles and Practice. New York, Churchill-Livingstone, 1991, pp 261-269.
27. Chien S, Sung LP: Molecular basis of red cell membrane rheology. Biorheology 1990;27:327-344.
28. Mohandas N, Chasis JA: Red blood cell deformability, membrane material properties and shape: Regulation by transmembrane, skeletal and cytosolic proteins and lipids. Semin Hematol 1993;30:171-192.
29. Lange Y, Gouch A, Steck TL: Role of the bilayer in the shape of the isolated erythrocyte membrane. J Membr Biol 1982;69:113-123.
30. Garnier M, Koutrsouris D, Hanss M: On the membrane determinant of erythrocyte deformability. Clin Hemorheol 1985;5:401-409.
31. Simon FR: Role of membrane lipids and fluidity in hepatic plasma membrane transport processes; in Tavoloni N, Berk PD (eds): Hepatic Transport and Bile Secretion: Physiology and Pathophysiology. New York, Raven Press, 1993, pp 297-312.
32. Galan AI, Munoz ME, Jimenez R: S-Adenosyl-methionine protects against cyclosporin A-induced alterations in rat liver plasma membrane fluidity and functions. J Pharmacol Exp Ther 1999;290:774-781.
33. Loss M, Winkler M, Schneider A, Brinkmann C, Manns M, Ringe B, Pichimayr R: Influence of long-term cyclosporine or FK 506 therapy on glucose and lipid metabolism in stable liver graft recipients. Transplant Proc 1995;27:1136-1139.
34. Chan FKL, Zhang Y, Lee SS, Shaffer EA: The effects of liver transplantation and cyclosporine on bile formation and lipid composition: An experimental study in the rat. J Hepatol 1998;28:329-336.
35. Andrade RJ, Lucena MI, Gonzalez-Correa JA, Garcia-Arias C, Gonzalez-Santos P: Short-term effect of various doses of cyclosporin A on plasma lipoproteins and its distribution in blood: An experimental study. Hum Exp Toxicol 1993;12/2:141-146.
36. Espino A, Lopez-Miranda J, Blanco-Cerrada J, Zambrana JL, Aumente MA, Paniagua JA, Blanco-Molina A, Jimenez-Pereperez JA, Rodriguez M, Perez-Jimez F: The effect of cyclosporine and methylprednisolone on plasma lipoprotein levels in rats. J Lab Clin Med 1995;125/2:222-227.
37. Buchwald H, O'Dea TJ, Menchaca HJ, Michalek VN, Rohde TD: Effect of plasma cholesterol on red blood cell oxygen transport. Clin Exp Pharmacol Physiol 2000;27:951-955.
38. Hussain MA, Kar S, Puniyani RR: Relationship between power law coefficients and major blood constituents affecting the whole blood viscosity. J Biosci 1999;24:329-337.
39. Reinhart WH: Molecular biology and self-regulatory mechanisms of blood viscosity: A review. Biorheology 2001;38/2-3:203-212.
40. Rosenson RS, Shott S, Tangney CC: Hypertriglyceridemia is associated with an elevated blood viscosity Rosenson: Triglycerides and blood viscosity. Atherosclerosis 2002;161:433-439.
41. Stamos TD, Rosenson RS: Low high density lipoprotein levels are associated with an elevated blood viscosity. Atherosclerosis 1999;146/1:161-165.
42. Rosenson RS, Shott S, Lu L, Tangney CC: Hypertriglyceridemia and other factors associated with plasma viscosity. Am J Med 2001;110:488-492.
43. Hernandez GN, Dabin C, del C Gayol M, Rasia ML: Haemorheological variables in a rat model of hypertriglyceridaemic obesity and diabetes. Vet Res Commun 2002;26:625-635.
44. Deters M, Klabunde T, Meyer H, Resch K, Kaever V: Effects of curcumin on cyclosporine-induced cholestasis and hypercholesterolemia and on cyclosporine metabolism in the rat. Planta Med 2000;69:337-343.
45. Lopez-Miranda J, Perez-Jimenez F, Gomez-Gerique JA, Espino-Montoro A, Hidalgo-Rojas L, Pedreno J, Jimenez-Pereperez JA: Effect of cyclosporin on plasma lipoprotein lipase activity in rats. Clin Biochem 1992;25:387-394.
46. Ballantyne CM, Podet EJ, Patsch WP, Harati Y, Appel V, Gotto AM Jr, Young JB: Effects of cyclosporine therapy on plasma lipoprotein levels. JAMA 1989;262/1:53-56.
47. Kuster GM, Drexel H, Bleisch JA, Rentsch K, Pei P, Binswanger U, Amann FW: Relation of cyclosporine blood levels to adverse effects on lipoproteins. Transplantation 1994;57:1479-1483.
48. Linde T, Sandhagen B, Backman U, Fellstrom B: Altered flow properties of blood and increased plasma fibrinogen in cyclosporin-treated renal allograft recipients. Nephrol Dial Transplant 1999;14:1525-1529.
49. First MR, Smith RD, Weiss MA, Schroeder TJ, Kant KS, Munda R, Stephens GW, Penn I, Alexander JW: Cyclosporine-associated glomerular and arteriolar thrombosis following renal transplantation. Transplant Proc 1989;21:1567-1570.
50. Levi M, Wilmink J, Büller HR, Surachno J, Ten Cate JW: Impaired fibrinolysis in cyclosporine-treated renal transplant patients. Transplantation 1992;54:978-983.